Dr. Talantov is a medical leader with Janssen Clinical Innovation based in California. He is responsible for development of novel clinical trial models, including direct-to-patient and hybrid trials and integration of digital technologies into clinical trials.
Prior to joining JCI, Dr. Talantov served as a medical director with Janssen Healthcare Innovation, where he led evidence-generation efforts across its portfolio and worked to develop and implement integrated care solutions in commercial settings.
Previously, Dr. Talantov was responsible for translational medicine components of early clinical development programs in immunology and in cardiovascular and metabolic therapeutic areas with Janssen R&D. Dr. Talantov had also led multiple projects around molecular cancer diagnostics with the Medical Devices sector of Johnson & Johnson.